Business
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
~ Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting scheduled for the second quarter of 2026 ~ ~ Progressing AMT-130 toward expected UK regulatory submission; MAA on track for third quarter of 2026 following successful pre-submission meeting with UK MHRA ~ ~ Enrollment in AMT-260 temporal lobe epilepsy program on track; clinical update from first cohort in Phase I/IIa study to be presented at the Epilepsy Foundation Pipeline Conference ~ ~ Presented updated data from
About this update from Uniqure N.v.
[{"type":"image","alt":"uniQure Inc.","displaySize":"","headline":null,"caption":"uniQure Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/cb8da6eec71588a1000495a1c5d28a54"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h5.5Z.Ho3JaFHspAcjq2vA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNA--/https://media.zenfs.com/en/globenewswire.com/cb8da6eec71588a1000495a1c5d28a54","width":300,"height":96}},"lazy":false},{"type":"text","content":"~ Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting scheduled for the second quarter of 2026 ~","length":123,"tagName":"p"},{"type":"text","content":"~ Progressing AMT-130 toward expected UK regulatory submission; MAA on track for third quarter of 2026 following successful pre-submission meeting with UK MHRA ~","length":161,"tagName":"p"},{"type":"text","content":"~ Enrollment in AMT-260 temporal lobe epilepsy program on track; clinical update from first cohort in Phase I/IIa study to be presented at the Epilepsy Foundation Pipeline Conference ~","length":184,"tagName":"p"},{"type":"text","content":"~ Presented updated data from AMT-191 Phase I/IIa in Fabry disease study showed sustained increases in α-Gal A Enzyme Activity and stable Lyso-Gb3 levels; subsequently all 11 dosed patients have discontinued enzyme replacement therapy ~","length":236,"tagName":"p"},{"type":"text","content":"~ Strong balance sheet with $586.6 million in cash, cash equivalents and current investment securities as of March 31, 2026 and runway into the second half of 2029 ~","length":165,"tagName":"p"},{"type":"text","content":"~ uniQure to host earnings call at 8:30 a.m. ET ~","length":49,"tagName":"p"},{"type":"text","content":"LEXINGTON, Mass. and AMSTERDAM, May 05, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.","length":319,"tagName":"p"},{"type":"text","content":"“During the first quarter of 2026, we remained focused on advancing AMT-130 to patients globally as rapidly as possible while executing across our broader pipeline,” said Matthew Kapusta, chief executive officer at uniQure. “We believe ...